



EFFECT OF ATROPINE SULPHATE ON OVARIAN ACTIVITIES IN ALBINO RATS

MADHU M.PATIL¹, SHARANGOUDA J.PATIL*² AND SARASWATI B.PATIL¹

¹Reproductive Biology laboratory, Department of Zoology, Gulbarga University Gulbarga-585106, Karnataka, India, ²Toxicology Laboratory, Bioenergetics and Environmental Science Division, National Institute of Animal Nutrition & Physiology (NIANP) Aduodi, Bangalore -560030, Karnataka, India. E mail: shajapatil@gmail.com

Received: 22 Dec 2009, Revised and Accepted: 27 Jan 2010

ABSTRACT

Atropine sulphate at the dose level of 0.1mg & 0.2mg/100gm body weight administration for 30 days to the cycling albino rats, caused decrease in the ovarian weight, showing a decreasing number of developing follicles, *Graafian* follicles and corpora lutea, and an increased number of atretic follicles in histological sections. The estrous cycles of these rats were irregular with prolonged diestrus and reduced proestrus, estrus and metaestrus phases also support the decreased estrogen synthesis. Responsible for cornification of vaginal smear in Atropine sulphate treated rats. The histometric changes of diameter of the ovarian follicles are reduced significantly. The total cholesterol content of the ovary was increased; protein and glycogen content were decreased.

Key words: Atropine sulphate, Rats, Ovary, *Graafian* follicle, Atretic follicle, Corpora lutea, Estrous cycle.

INTRODUCTION

Atropine, is a naturally occurring alkaloid of plant "*Atropia belladonna*". The other sources are *Datura innoxia*, *Datura stramonium*. It is a competitive antagonist of muscarinic cholinergic drug. Generally, Atropine sulphate is used as atropine sulphate injection and chemically designed as 1 α H, 5 α H-Tropan-3- α OL (\pm) - tropate (ester) sulphate (2:1) (salt) monohydrate, (C₁₇H₂₃NO₃)₂ H₂SO₄ H₂O¹. A single subcutaneous injection of atropine on proestrus day delays ovulation for several hours in mice². The studies of Redmond³ indicate that, the atropine effectively blocks the progesterone induced ovulation in rats. In male rats the administration of this drug into autonomic nerve inhibits the testicular development⁴. All the facets of activity exhibited by nervous system are susceptible to pharmacological manipulation. The anaesthetic gases, the aliphatic alcohols, the barbiturates, the nicotine and atropine, interfere in the activities of the CNS therapy modify the action of the gonads and associated organs. CNS depressants acts on the hypothalamus and inhibit the release of gonadotrophin releasing hormone (GnRH) and corticotrophin releasing factor (CRF) thus decreasing the circulating concentrations of luteinizing hormone (LH), follicle stimulating hormone (FSH), adrenocorticotrophic hormone (ACTH) and β -endorphin⁵. Secretions of pituitary gonadotrophins are regulated by brain and neurons situated in the anterior parts of the hypothalamus that synthesize the GnRH⁶. According to several investigators CNS influencing drugs inhibit the release of FSH and LH from the pituitary action through hypothalamus, blocking the neural stimulus to the gonadotrophin releasing hormone⁷⁻⁹. Though there are many indirect evidences of atropine sulphate on reproduction, so far, no direct action has been reported. Therefore, in the present study is aimed to understand the effect of Atropine sulphate on ovarian activities which are dependent on hypophysical gonadotrophins in albino rats^{10, 11}.

MATERIALS AND METHODS

Animals

Sexually matured, healthy, colony bred virgin female rats of Wistar strain; aged 3 months and weighing 160-180g were used for the experimentation. The rats were housed in polypropylene cages measuring 12"×10"×8", under well ventilated animal house conditions (Temperature: 28-31°C; Photoperiod: 12h natural light

and 12h darkness: humidity: 50-55%). The rats were fed with balanced diet as per CFTRI, Mysore, INDIA formula and water *ad libitum*. The rats were divided into three groups of six animals each.

Group 1: Received 0.2ml saline/100g body weight for 30 days.

Group 2: Received 0.1mg Atropine sulphate in 0.2ml saline/100gm body weight for 30 days.

Group 3: Received 0.2mg Atropine sulphate in 0.2ml saline/100gm body weight for 30 days.

The treatment was started from estrus phase only, as the ovarian activities changes markedly from one phase to another phase of oestrous cycle. The saline or Atropine sulphate was administrated intraperitoneally everyday between 10:00 to 11:00AM

All the rats were sacrificed on 31st day, 24 hour after the last treatment. The ovaries were dissected out immediately and separated out from the adherent tissue and weighed to the nearest mg on an electronic balance. Organ from one side of each rat were fixed in Bouin's fluid, embedded in paraffin wax, sectioned at 5 μ m, stained with haemotoxylin-eosin for histological studies. Ovarian follicular diameter and morphologies were used to classify follicles by using established method^{12, 13}. Morphometric studies of the ovary were made by using stage and ocular micrometer and organ from the other side was used for biochemical estimations like protein¹⁴, glycogen¹⁵ and cholesterol¹⁶.

RESULTS

Changes in the body weight [Table-1]

There is non-significant change in the body weight after administration of Atropine sulphate.

Changes in the Ovary

Gravimetric changes [Table-2]

Administration of 0.1mg Atropine sulphate showed almost significant reduction (p<0.05) in the ovarian weight with 15.56% inhibition. But, the administration of 0.2mg atropine sulphate showed significant (p<0.01) reduction in the ovarian weight with 45.81% inhibition when compared that of saline treated control.

Table 1: Effect of of Atropine Sulphate on the body weight of albino rats

Treatment	Initial body weight	Final body weight	% Increase	Weight of the Ovary	% Inhibition
Saline	155.25 ± 2.95	168.96 ± 0.97	8.83	39.57 ± 1.91	—
Atropine sulphate (0.1mg/100g body wt.)	157.42 ± 1.80	170.37 ± 2.85	8.22	33.41 ± 1.01*	15.56
Atropine sulphate (0.2mg/100g body wt.)	153.76 ± 2.54	165.23 ± 2.70	7.46	21.44 ± 1.10**	45.81

Duration: 30days, 6 animals are maintained in each group. M ± S.E. = Mean ± Std. Error, * = P<0.05, ** = P<0.01, *** = P<0.001

Biochemical changes [Table -2]

The Atropine sulphate administration has shown inhibitory effect on ovarian activities. Cholesterol the precursor for steroid biosynthesis is increased significantly (p<0.01) with 0.1mg and highly significant (p<0.001) with 0.2mg of Atropine sulphate administration. The

protein content is decreased significantly (p<0.001) with 0.1mg and highly significantly (p<0.001) with 0.2mg treatment of Atropine sulphate, whereas, glycogen content of the ovary, the energy reservoir of female reproductive activities were decreased highly significantly (p<0.001) with both the doses.

Table 2: Effect of Atropine Sulphate on the Biochemical changes of Ovary

Treatment	Weight of ovary	Cholesterol (µg/mg ovary)	Protein (µg/mg ovary)	Glycogen (µg/mg ovary)
Saline	39.57 ± 1.91	27.50 ± 1.37	23.53 ± 0.43	6.13 ± 0.29
Atropine sulphate (0.1mg/100g body wt.)	33.41 ± 1.01*	32.28 ± 0.63**	18.09 ± 0.38**	3.05 ± 0.13***
Atropine sulphate (0.2mg/100g body wt.)	21.44 ± 1.10**	36.21 ± 0.30***	15.75 ± 0.35***	2.08 ± 0.16***

Duration: 30days, 6 animals are maintained in each group. M ± S.E. = Mean ± Std. Error, * = P<0.05, ** = P<0.01, *** = P<0.001

Histological changes [Table -3; Figure-1-3]

The histological sections of the ovaries of Atropine sulphate administration has decreased in number of healthy follicles and increased in the number of regressing follicles.

The number of healthy follicles like primary follicles has reduced significantly (p<0.01) with 0.1mg and highly significantly (p<0.001) with 0.2mg doses. The decrease in the number of secondary follicles

non-significantly with 0.1mg and significantly (p<0.05) and with 0.2mg doses, the highly significant reduction (p<0.001) with both the doses and number of corpora lutea which are formed after the ovulation were decreased significantly (p<0.01) with 0.1mg and highly significantly (p<0.001) with 0.2mg of Atropine sulphate administration. The regressing follicles like atretic follicles were increased almost significantly (p<0.05) with 0.1mg and significantly with 0.2mg of Atropine sulphate administration.

Table 3: Effect of Atropine Sulphate on the Histological changes of Ovary

Treatment	Primary Follicles	Secondary Follicle	Graafian Follicles	Atretic Follicles	Corpora Lutea
Saline	3.80 ± 0.24	3.50 ± 0.16	3.70 ± 0.15	1.30 ± 0.15	4.70 ± 0.82
Atropine sulphate (0.1mg/100g body wt.)	2.90 ± 0.23*	3.40 ± 0.21	2.20 ± 0.24***	1.67 ± 0.16*	3.50 ± 0.16**
Atropine sulphate (0.2mg/100g body wt.)	2.30 ± 0.29***	3.02 ± 0.21*	1.50 ± 0.16***	1.90 ± 0.17**	3.10 ± 0.23***

Duration: 30 days, 6 animals are maintained in each group. M ± S.E. = Mean ± Std. Error, * = P<0.05, ** = P<0.01, *** = P<0.001




Fig. 1: Photomicrograph of ovary treated with vehicle showing normal fully developed primary, secondary follicles and Graafian follicle with healthy oocyte (x 100).




Fig. 2: Photomicrograph of ovary treated with 0.1mg of Atropine Sulphate showing under developed and degenerating follicles (x 100).




Fig. 3: Photomicrograph of ovary treated with 0.2mg of Atropine Sulphate showing degenerative follicles (x 120).

Histometric changes of ovarian components [Table-4; Figure-1-3]

The histometric measurement of ovarian diameter of the ovarian components like primary follicles, secondary follicles, Graafian follicles, atretic follicles and corpora lutea were decreased their diameter almost significant ($p < 0.05$) with 0.1mg and significantly ($p < 0.01$) with 0.2mg of Atropine sulphate administration, these results are parallel to that of ovarian weight and number of follicles of the experimental studies.

Changes in the oestrous cycle [Table -5]

The duration of proestrus is reduced significantly ($p < 0.01$) with 0.1mg and highly significant ($p < 0.001$) with 0.2mg doses, whereas, the reduction of estrus and metaestrus phases were highly significant ($p < 0.001$) with both the doses of experimental animals. The diestrus phase was increased highly significantly ($p < 0.001$) with both doses of Atropine sulphate administration.

Table 4: Effect of Atropine Sulphate on the Histometric changes of Ovary

Treatment	Primary Follicles	Secondary Follicle	Graafian Follicles	Atretic Follicles	Corpora Lutea
Saline	9.09 ± 0.09	26.47 ± 0.28	36.16 ± 0.88	34.12 ± 0.25	39.20 ± 0.21
Atropine sulphate (0.1mg/100g body wt.)	7.19 ± 0.14*	21.94 ± 0.37*	29.02 ± 0.18*	31.02 ± 0.24*	34.02 ± 0.24*
Atropine sulphate (0.2mg/100g body wt.)	5.97 ± 0.27**	15.03 ± 0.30**	21.08 ± 0.21**	28.14 ± 0.29**	29.20 ± 0.21**

Duration: 30 days, 6 animals are maintained in each group. M ± S.E. = Mean ± Std. Error, * = $P < 0.05$, ** = $P < 0.01$, *** = $P < 0.001$

Table 5: Effect of Atropine Sulphate on the duration of various stages of Estrous Cycle in albino rats

Treatment	Proestrus	Estrus	Metaestrus	Diestrus
Saline	4.62 ± 0.30	4.21 ± 0.31	3.98 ± 0.06	18.08 ± 0.32
Atropine sulphate (0.1mg/100g body wt.)	2.89 ± 0.18**	2.56 ± 1.42***	1.98 ± 0.14***	21.97 ± 1.28***
Atropine sulphate (0.2mg/100g body wt.)	2.34 ± 0.24***	2.09 ± 0.12***	1.87 ± 0.02***	24.01 ± 1.68***

Duration: 30 days, 6 animals are maintained in each group. M ± S.E. = Mean ± Std. Error, * = P<0.05, ** = P<0.01, *** = P<0.001

DISCUSSION

In the present investigation the weight of ovary is reduced significantly due to the administration of Atropine sulphate. As the drug is administered between 10 to 11:00 AM every day, there is possibility of covering the so called "Critical period" for cyclic LH surge, necessary for ovulation; thus postponing the ovulation for one day by interfering with 24 hours periodicity for gonadotrophin release^{17,18}. Low levels of plasma FSH and LH with high concentration of pituitary gonadotrophin and prolactin are observed after Atropine sulphate administration by some investigators^{7,9}. It is well known that hypothalamus regulates the rhythmic release of pituitary gonadotrophin i.e., FSH, LH and prolactin through the neural stimulus to gonadotrophin releasing hormone (GnRH)¹⁹. The orderly event of follicular growth and ovulation depends upon the pituitary FSH, LH & prolactin. FSH stimulates the differentiation of granulosa cells and promotes the follicular development²⁰⁻²².

In the present study the ovaries of treated rats have reduced significantly with retarded follicular growth, differentiation of granulosa cells in the follicles, underdeveloped follicles and reduction in the ovulatory follicles may be attributed to the non availability of gonadotrophin and these are very essential for maintenance of ovarian activities.

The continuous presence of FSH within the follicles prevents the follicle undergoing atresia²³. The large number of atretic follicles along with degeneration of granulosa cells and disappearance of antrum in Atropine sulphate treated rats may be due to inadequate supply of pituitary FSH. As ovulation needs increased concentration of plasma LH and FSH²⁴⁻²⁶. Atropine sulphate might have resulted in the inhibition gonadotrophin release resulting in the blockade of ovulation as evidenced by decreased in the number of freshly formed corpora lutea.

The low protein content of ovary indicates the retarded ovarian growth as FSH is essential for protein synthesis in gonads²⁷. High accumulation of cholesterol content in the ovary of drug treated rats may be attributed to the lowered steroidogenesis which is dependent on availability of pituitary gonadotrophins^{28,29}.

The energy source for female reproductive activities is ovarian glycogen that is oestrogen dependent³⁰. The supply of glycogen to different reproductive organs in female has been reported to be controlled by the ovarian estrogen and progesterone³¹. The decreased level of glycogen in the Atropine sulphate treated ovary may be due to low ovarian steroidogenesis, which is attributed to low availability of pituitary gonadotrophins.

Oestrous cycle is regulated by the secretion and release of ovarian estrogen and progesterone production which in turn controlled by pituitary gonadotrophins. The administration of atropine sulphate prolongs the length of diestrus phase significantly resulting in decrease in number of cycles. This may be the effect of reduced

steroidogenesis of the ovary as the estrogen which is essential for cornification of vaginal epithelial cell during estrus phase.

REFERENCES

- Schmidt H Jr, Moak SJ, Van VG Meter Atropine Depression of Food and Water Intake in the Rat. *Am J Physiol* 1957; 192: 543-545.
- Okamoto MT A study of releasing of ovulating hormone in IVCS strain mice: I. Delay in ovulation treated by Nembutal. *Jap J Anim Reprod* 1974; 16: 52-58.
- Redmond WC Ovulatory response to brain stimulation or exogenous luteinization or exogenous lutenizing hormone in progesterone treated rats. *Endocrinol* 1968; 49: 162-168.
- Murano S The role of autonomic nervous system. Development of testes. *Neuroendocrinol* 1968; 61: 19-24.
- Jaff JH, Martin WR. Opiod analgesics and antagonists. In Goodman I.S. Rall WR, Murad Feeds. The pharmacological basis of therapeutics. Mac Millan Publishing Co., 1985. p. 491-531.
- Krieger DT, Porlow MJ, Gibson TF, Davies EA, Zimmerman M, Ferin, et al. Brain grafts reverse hypogonadism of GnRH deficiency. *Nature* 1982; 293: 468-471.
- Blake CA, Scaramuzzi RJ, Norman RL, Kanematsu S, Sawyer CH Effect of nicotine on the proestrous ovulatory surge of LH in the rat, *Endocrinol* 1972; 91: 1253-1258.
- Blake CA Paradoxical effects of drugs acting on the central nervous system on the preovulatory release of pituitary luteinizing hormone in pro-oestrous rats. *J Endocrinol* 1978; 79: 319-326.
- Anderson K, Eneroth P, Agnati LF Effects of acute central and peripheral administration of nicotine on hypothalamic catecholamine nerve terminal systems and on the secretion of adenohipophyseal hormones in the male rats. *Med Biol* 1982 a; 60: 98-111.
- Patil SB, Rao AP Retardation of ovarian compensatory hypertrophy by Atropine sulphate in unilaterally ovariectomized rats. *Cur Sci* 1992; 18: 87-91.
- Malshetty VB, Patil SR, Patil SB Pethidine induced changes in ovarian follicular kinetics and biochemical parameters in albino rats. *Ori Pharm Exp Med* 2006; 6: 300-305.
- Hirshfield AN Compensatory ovarian hypertrophy in the long-term hemicstrate rat: size distribution of growing and atretic follicles. *Biol Reprod* 1983; 28: 271-278.
- Sanjay VS, Joshi BN Melatonin and exposure to constant light/darkness affects ovarian follicular kinetics and estrous cycle in Indian desert Gerbil Meriones hurricane (Jordan). *Gen Comp Endocrinol* 1997; 108: 352-357.
- Lowry OH, Rosenbrough NJ, Earr NL, Randoll RJ Protein measurement with folic-phenol reagent. *J Biol Chem* 1951; 193: 265-276.
- Carrol NV, Langelly RW, Row RH Glycogen determination in liver and muscle by use of anthrone reagent. *J Biol Chem* 1956; 20: 583-593.

16. Peters J, Vanslyke DD. Qualitative Chemical Chemistry: Vol I, Williams and Wilkins eds., Baltimore; 1946.
17. Lawton I, Sawyer CH Timing of gonadotrophin and steroid secretion at diestrus in the rat. *Endocrinol* 1968; 83: 831
18. Sindgi SB. Effect of barbiturates on ovarian growth and pregnancy in albino rats. Ph.D. thesis, Karnataka University, Dharwad; 1975.
19. Carmel PW, Araki S, Ferin M Pituitary stalk portal blood collection in rhesus monkeys : Evidence of or pulsatile release of gonadotrophin releasing hormone (Gn-RH). *Endocrinol* 1976; 99: 243.
20. Channing CP Influences of the *in-vivo* and *in-vitro* hormonal environment. *Recent Prog Horm Res* 1970; 26: 589.
21. Goldenberg RI, Vaitukaitis JL, Ross TG Estrogen and follicle stimulating hormone interactions on follicle growth in rats. *Endocrinol* 1972; 90: 1492-1498.
22. Richards JS, Ireland JJ, Rao MC, Bernath GA, Midgley AR Jr, Reichert LE Jr Ovarian follicular development in the rat: hormone receptor regulation by estradiol, follicle stimulating hormone and luteinizing hormone. *Endocrinol* 1976; 99: 1562-1570.
23. Peters H, Byskov AG, Himelstein AR, Braw, Faber M Follicle growth : The basic event in the mouse and human ovary *J Reprod Fertil* 1975;45: 559-564.
24. Young EL, Biard DT, Hillier SG Melatonin gonadotropin stimulated growth and differentiation on human granulosa cell by 3'-5'- monophosphate: One molecule, two genes. *Clin Endocrinol* 1992; 37: 51-55.
25. Wang X, Greenwald GS Hypophysectomy of the cyclic mouse. I. Effects on Folliculogenesis, oocyte growth, and follicle stimulating hormone and chorionic gonadotrophin receptors. *Biol Reprod* 1993; 48: 585-594.
26. Greenwald GS, Roy SK. Follicular development and its control. In: *The Physiology of Reproduction*, Second edition, Knobil, E. and Neill, J. D. (Eds), Raven Press Ltd., New York, 1994. p. 629-724.
27. Means, AR Biochemical effects of follicle stimulating hormone on the testis, 1975.
28. Jalikhani BL. Ovarian steroids, In: *Text book of biochemistry and human biology*, Talwar, G.P.9(Ed). Vertical Hall, Ind Pri Ltd New Delhi, 1980. p.805.
29. Findlay JK. *Molecular biology of the female reproductive system*. Academic Press, California, 1994.
30. Walaas O Effect of oestrogens on the glycogen contents of the rat uterus. *Acta Endocrinol* 1952; 10: 175-192.
31. Gregoire AT, Ramsay H, Adams A The effects of various doses of estradiol and glycogen deposition in the rat uterus, Cervix and Vagina. *J Reprod Fert* 1967; 14: 231-235.